[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Hot take on $ABCL's XXX after the disappointing XX% placebo-adjusted remission rate for Sanofi's amlitelimab in its Phase X COAST-1 trial. Both molecules target the early OX40L checkpoint for inflammation in AtD. $SNY's results are encouraging in terms of MoA validation but weren't quite up to the expectations set by Dupixent (27% remission at Week XX in CHRONOS). AbCelleras molecule has an engineered Fc that provides an extended half-life alongside Fc silencing. This could translate to less frequent dosing and more consistent blockade of OX40L potentially resulting in improved remission"
X Link @iHooghvorst 2025-10-22T11:47Z 3366 followers, 5391 engagements
"$ABCL's balance sheet is primed - execution is all that is left"
Reddit Link @Stonkstronaut 2025-06-25T00:24Z X followers, XX engagements